Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Stem Cell Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSPAN3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSPAN3 Extracellular Loop 2 (LEL/EC2) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View TSPAN3 Products |
| Gene Delivery | TSPAN3 Promise-ORF / Lentivirus Full-length human TSPAN3 ORF for stable cell line generation. Ideal for conformational-dependent antibody screening. |
View TSPAN3 Products |
| Benchmark Ab | Anti-TSPAN3 Recombinant Antibody Recombinant positive control derived from benchmark research clones. |
View TSPAN3 Products |
| Validator | TSPAN3 siRNA Set Target-specific siRNA pool for knockdown verification in functional assays. |
View TSPAN3 Products |
| Related Target A | TSPAN8 Highly homologous tetraspanin family member; critical for off-target selectivity and counter-screening. |
View TSPAN8 Products |
| Related Target B | CD151 Tetraspanin partner involved in integrin signaling; synergizes with TSPAN3 in cell migration and metastasis. |
View CD151 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane conformation preservation | Lentivirus premade particles available for generating stable, high-expression cell lines to maintain native 4-TM folding. |
| Subfamily cross-reactivity (Off-target effects) | High-purity recombinant LEL/EC2 proteins from TSPAN8 and CD151 for rigorous counter-screening panels. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog as positive controls. |
| False Positives | In vitro validated siRNA pools included to confirm target-specific phenotypic knockdown. |
Live TSPAN3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSPAN3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T therapies targeting cancer stem cells. As first-generation therapies reach the clinic, the next wave of R&D is targeting TSPAN3's role in therapeutic resistance and the tumor microenvironment.
TSPAN3 (Tetraspanin-3) is emerging as a critical driver of cancer stem cell self-renewal and drug resistance, particularly in acute myeloid leukemia (AML) and glioblastoma. By scaffolding key signaling receptors like CXCR4 and integrins, TSPAN3 facilitates niche homing and survival signals. Therapeutic targeting strategies are moving beyond simple ligand-blocking toward internalization-dependent modalities that can selectively eliminate high-TSPAN3-expressing cancer stem cell populations while sparing healthy progenitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Medical Centers, Biotech Startups | Acute Myeloid Leukemia (AML) | Conformational Binding (Need full-length TSPAN3 overexpressing cell lines via Lentivirus) |
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biopharma | Solid Tumors, Glioblastoma | Internalization Assay (Need high-purity recombinant LEL/EC2 proteins for binding kinetics) |
| CAR-T / Cell Therapy | Cell Therapy Developers | Refractory Hematological Malignancies | Selectivity Assay (Need homologous Tetraspanin family proteins like TSPAN8 for off-target screening) |